Alpine Immune Sciences Inc (NASDAQ: ALPN) closed the day trading at $37.45 down -0.27% from the previous closing price of $37.55. In other words, the price has decreased by -$0.10 from its previous closing price. On the day, 776792 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of ALPN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 7.86. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $44.
On October 18, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.
On October 17, 2023, Berenberg started tracking the stock assigning a Buy rating and target price of $18.Berenberg initiated its Buy rating on October 17, 2023, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 26 ’24 when Rickey James Paul sold 117,764 shares for $23.32 per share. The transaction valued at 2,745,830 led to the insider holds 0 shares of the business.
Rickey James Paul sold 236 shares of ALPN for $5,192 on Jan 25 ’24. The insider now owns 0 shares after completing the transaction at $22.00 per share. On Dec 28 ’23, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 1,364,849 shares for $18.35 each. As a result, the insider received 25,049,034 and left with 264,315 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALPN now has a Market Capitalization of 2.45B and an Enterprise Value of 2.14B. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.69 while its Price-to-Book (P/B) ratio in mrq is 6.89. Its current Enterprise Value per Revenue stands at 36.29 whereas that against EBITDA is -68.03.
Stock Price History:
Over the past 52 weeks, ALPN has reached a high of $42.88, while it has fallen to a 52-week low of $6.39. The 50-Day Moving Average of the stock is 30.99, while the 200-Day Moving Average is calculated to be 17.69.
Shares Statistics:
Over the past 3-months, ALPN traded about 1.12M shares per day on average, while over the past 10 days, ALPN traded about 1.51M shares per day. A total of 60.35M shares are outstanding, with a floating share count of 47.05M. Insiders hold about 28.22% of the company’s shares, while institutions hold 68.32% stake in the company. Shares short for ALPN as of Feb 29, 2024 were 4.43M with a Short Ratio of 3.96, compared to 3.34M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.76% and a Short% of Float of 11.01%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.51, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.3 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.23 and -$1.97 for the fiscal current year, implying an average EPS of -$1.69. EPS for the following year is -$1.91, with 7 analysts recommending between -$1.16 and -$2.45.
